In this issue:
Secukinumab superior to adalimumab for skin symptoms in concomitant PsA/Ps
Low risk of malignancy with secukinumab exposure
FMT doesn’t provide a benefit in PsA
Tildrakizumab improves joint and skin manifestations but not dactylitis or enthesitis
Cardiovascular risk factors more prevalent in gout and female PsA patients
Long-term safety data of tofacitinib in patients with inflammatory conditions
Even patients classified as having a low disease activity have a substantial disease burden
Pregnancy in women with PsA
The incidence and risk factors for venous thromboembolic events in PsA
Upadacitinib maintains efficacy on longer-term follow-up
Please login below to download this issue (PDF)